Recent Updates
Recently added Catalysts
FATE

Phase 1 Translational Assessment of an Off-The-Shelf CAR NK Cell Armed with Alloimmune Defense Technology for Conditioning-free Therapy

Key Takeaway: The article discusses a Phase 1 translational assessment of an off-the-shelf CAR NK cell therapy that utilizes alloimmune defense technology. This therapy aims to provide conditioning-free treatment options. However, the article lacks specific details about the study's outcomes or implications.
Price reaction · baseline $1.07 (2025-05-16 close) · hit pre-market · 4 other FATE headline(s) in the window, move may be shared
day 0 close
+14%
day 1 · peak
+16.8%
day 3
+12.1%

Market Sentiment Analysis

Full Press Release Details

• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Last updated: May 19, 2025